WINOOSKI, Vt.—The work won’t likely be finished until the end of the year, but BioTek Instruments celebrated the start of a $4-million, 22,000-square-foot facility expansion during a company-wide event held July 18, which featured such guests as U.S. Sen. Patrick Leahy and U.S. Rep. Peter Welch—both representing Vermont in the U.S. Congress—and Vermont’s Gov. Peter Shumlin and Lt. Gov. Phil Scott.
The company says it needs the increased space to support what it calls its “rapidly growing manufacturing and design needs.”
“Our truest successes are not defined by dollars, but rather by making shared positive impacts throughout our state, our country and across the entire world, and I’m proud of what we have accomplished together,” said Briar Alpert, BioTek’s president and CEO. “Today, our world-renowned products are used to find cures and treatments for a wide array of diseases and disorders, to ensure the safety and efficacy of resources we depend upon and to uncover new uses for existing materials. We develop and manufacture all of these products right here in Vermont, and we’re a working example of home-grown success reaching a global scale.”
“As a global company, BioTek has a reach that spans borders. Briar and Adam [Alpert] have chosen to grow their company right here, at home in Vermont,” commented Leahy at the ceremony. “As I continue to work at the federal level to support Vermont businesses, and on increased access to capital and investment in our state’s infrastructure, their decision serves as an inspiration and a model to many other Vermont businesses that also plan to grow.”
BioTek is a worldwide leader in the design, manufacture and sale of microplate instrumentation and software. These technologies are used to aid life-sciences research, facilitate drug discovery, provide rapid and cost-effective analysis and enable sensitive, accurate quantification of molecules across diverse applications.
More than two weeks earlier, BioTek also affirmed its ongoing investment across the North American microplate-based technology market with an expansion of its business in Canada.
“Canada’s life-science sector continues to yield high-quality scientific research, supported by federal and provincial government focus and investments,” noted Dr. Charles Amirmansour, previously BioTek’s applications and business development manager and now appointed as the Canadian country manager. “By expanding our footprint here, we can continue to provide first-in-class local, comprehensive and immediate sales, applications and service support to this rapidly growing market.”
